The Official Biotech Investments M&A Target List for 2020 and 2021
Most people investing in biotech stocks know that there are always lots of buyout rumors in the news about potential biotech takeover candidates and targets as one can benefit of a massive premium in the case of a buyout. In 2019, more than 25 biotech companies have been snapped by big pharmaceutical companies. Most likely, biotech merger & acquistions (M&A) will also be extremely active for the rest of 2020 and in 2021.
But which are really the most promising takeover candidates in biotech industry? And are these also the best biotech stocks to buy now? Please find below the answers to these questions in the official Biotech Investments M&A target list containing the hottest acquisition targets in biotech industry for 2020 and 2021.
1. Alexion Pharmaceuticals
Alexion Pharmaceuticals is specialized on the development and commercialization of drugs for rare diseases. The company is already one of the hottest takeover candidates in biotech industry for years. Market cap: $22.86 billion.
2. Alnylam Pharmaceuticals
Alnylam Pharmaceuticalsis a Cambridge (MA)-based biopharmaceutical company focussing on the development and commercialization of RNA interference therapeutics for genetic diseases. Besides a highly promising clinical pipeline, the company has with ONPATTRO (Patisiran) and GIVLAARI (Givosiran) two approved drugs for the management of hATTR amyloidosis and acute hepatic porphyria (AHP). Market cap: $15.43 billion.
3. Axsome Therapeutics
Axsome Therapeutics is a clinical-stage biotech company developing innovative drugs for the treatment of central nervous system (CNS) disorders such as depression and migraine. Shares of Axsome Therapeutics rose more than 3500% in 2019 after the company has achieved significant progress with its clinical research pipeline. Market cap: $2.87 billion.
4. Clovis Oncology
Clovis Oncology’s lead drug Rubraca is approved for the treatment of metastatic castration-resistant prostate cancer as well as for the treatment of recurrent ovarian cancer. In addition, the company has a very robust pipeline for various oncologic indications. Market cap: $437.49 million.
5. CRISPR Therapeutics
CRISPR Therapeutics is based in Zug (Switzerland) and is developing tranformative genetic medicines for serious human diseases including hemoglobinopathies and cancer. This company is definetively in the focus of big pharma. Market cap: $6.23 billion.
6. Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a specialist for precision oncology. In June 2020, the FDA approved Deciphera’s lead drug QINLOCK (Ripretinib) for the treatment of patients with gastrointestinal stromal tumors (GIST). The company is also evaluating Ripretinib’s therapeutic potential for the treatment of other solid tumors and has a pipeline with several other drug candidates. Market cap: $2.52 billion.
7. Intercept Pharmaceuticals
Intercept Pharmaceuticals is an American biopharmaceutical company working on the development of novel synthetic bile acid analogs for the to treatment of chronic liver diseases, such as primary biliary cholangitis (PBC) and non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH). With OCALIVA (Obeticholic Acid), Intercept can market since 2016 its first drug for the treatment of PBC in the United States. Market cap: $1.60 billion.
8. Intra-Cellular Therapies
Intra-Cellular Therapies develops biopharmaceutical drugs to treat severe neuropsychiatric and neurological diseases such as bipolar depression and Parkinson’s disease. In December 2019, CAPLYTA was approved by the FDA for the treatment of adult patients with schizophrenia. Market cap: $1.25 billion.
9. Myovant Sciences
Myovant Science is a small pharmaceutical company with offices in Brisbane (California) and Basel (Switzerland). Myovant’s lead drug candidate is Relugolix, an investigational molecule with blockbuster potential for the management of androgen-sensitive prostate cancer and uterine fibroid. Uterine fibroids are non-cancerous tumors which develop inside the uterine wall and can result in excessive bleeding. Myovant is also investigating Relugolix in a phase 3 trial for the treatment of endometriosis. Market cap: $1.75 billion.
10. Sarepta Therapeutics
Sarepta Therapeutics is specialized on gene therapy and has with EXONDYS 51 (Eteplirsen) VYONDYS 53 (Golodirsen) two approved treatment for Duchenne muscular dystrophy. In addition, the Americans have a very broad research pipeline for various genetic conditions. Market cap: $11.69 billion.
Are you interested in getting regular updates on the best biotech stocks to buy? You can find lots of great articles as well an update on the Biotech Investments Model Portfolio in our free monthly Biotech Investments MAGAZINE. Do you want to subscribe?
- Just send an email with “MAGAZINE” to email@example.com
- You will receive it immediately by email
- Enjoy reading, it’s entirely free